Introduction: Multinational Association of Supportive Care of Cancer (MASCC) index score is a clinical tool to predict outcomes in Febrile Neutropenia patients. This risk-index score has been authenticated in international trials however local data is deficient. We aimed to determine hospital based incidence rate of serious complications in admitted chemotherapy induced febrile neutropenia patients presenting to a tertiary care hospital. We also aimed to compare proportions of serious medical complications in patients having MASCC score <21 or ≥21. Methods: A hospital based prospective close cohort study was designed and conducted at Oncology wards of The Aga Khan University from February to August 2014. Total of 88 patients, aged 16 and above, with chemotherapy induced febrile neutropenia were identified and divided on the basis of MASCC Score into low or high risk {exposure} groups. Follow up was done from day of admission (day zero) to discharge. Outcome was assessed in terms of development of serious complications. Hospital based incidence rate was estimated. The associations between outcome and qualitative variables were evaluated by using Pearson Chi-square and Fisher's exact test. Results: Hospital based incidence rate of febrile neutropenia admission was 5.98%, 95%CI [4.88% -7.08%]. Out of 88 patients with chemotherapy induced febrile neutropenia 85.2% patients were in the high risk group and 14.8% in the low risk group. Serious complications were found in 21.33% and no patients in high and low risk group respectively. Age > 60 (p = 0.039), 
MASCC score < 15 (p = 0.002) and an albumin < 2.5 mg/dl (p = 0.046) was associated with higher chance of developing serious complications. Sensitivity, specificity, positive and negative predictive value of MASCC score in predicting risk of serious complications was 21.33%, 100%, 100% and 18.06% respectively. Conclusion: MASCC risk-index score is a useful tool to identify patients at low risk of complications. Hospital based incidence rate of serious complications was 18.2%.
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Introduction
Febrile neutropenia (FN) is a common complication of chemotherapy. It is considered a medical emergency, in general requiring hospital admission and broad spectrum empiric antibiotics [1] . Among patients receiving chemotherapy 10% -50% of patients with solid tumours and 80% of those with hematologic malignancies are said to develop FN [2] . Around 10% -25% patients have documented bacteraemia with most patients having prolonged or severe neutropenia [3] [4] [5] . Such episodes lead to delay in treatment which may compromise outcomes in potentially treatable tumours [6] . Febrile neutropenia may be potentially lethal, with one study reporting inpatient mortality with FN as high as 9.5% [7] . Mortality varies from 5% in patients with solid tumours to around 11% in patients with haematological tumours [8] . Factors associated with high risk of mortality include pneumonia, invasive fungal infections, lung disease, renal disease, liver disease, cerebrovascular disease, congestive cardiac failure, pulmonary embolism and lung carcinoma [7] . Factors associated with a favourable outcome are said to be an albumin level of >2.5 mg/dl, low disease burden, and an absence of respiratory infection [9] . Proven bacteraemia is associated with worst outcomes, with mortality rates of 5% in Gram-positive bacteraemia and 18% in Gram-negative bacteraemia [8] .
Various instruments have been established to predict which cases are at high risk for complications. The purpose of such models is to predict the risk of complications at the commencement of FN episode, and to recognize which patient subset would be eligible for outpatient management and less intensive antibiotic therapy. Two such models have been used for risk stratification, which include to stratify patients into high or low risk and predict their possible outcome, with a score of 21 or more putting the patient at low risk of complications and mortality [11] . The results of this study predicted low risk patients (with a risk index score of ≥21) with a positive predictive value of 91%, specificity of 68%, and sensitivity of 71% [11] .
Baskaran et al. reported a total of 116 cases of febrile neutropenia out of whom medical complications occurred in 34% of cases. Of the patients identified as low risk, 17.1% developed serious medical complications while patients in the high-risk group, 85% developed serious medical complications [9] .
There have been various prospective studies to validate the MASCC scoring system; however most of them have been conducted in developed countries [9] [11]. Hence we carried out this study to assess if MASCC scores of high risk and low risk and consequently high or low risk of complications are applicable in our part of the world. By identifying patients at low risk of complications, a less aggressive treatment may be given (early hospital discharge or outpatient therapy), thus reducing the cost of hospital stay, chances of overtreatment and appropriate use of resources and at the same time, identifying patients with high risk and appropriately treating them [12] .
The MASCC risk index score is based on seven independent factors, present at the beginning of FN episode. These seven factors and their weight are given in Table 1 .
The list of serious complications is detailed in Table 2 . We hypothesized that patients with low MASCC score are at a higher risk of developing serious complications as compared to those with a high score. The primary objective of this study was to estimate hospital based incidence rate of serious complications in cancer patients admitted with febrile neutropenia.
We also aimed to compare proportions of serious medical complications in patients having MASCC score < 21 or ≥21.
Methods

Overview and Study Participants
We adopted a prospective close cohort study design to collect data from Febru- ary to August 2014 from the Oncology wards of The Aga Khan University (where both haematology and solid tumours are treated) which is one of the tertiary care hospitals in Karachi, Pakistan receiving patients from all over the country. We recruited a cohort of 88 chemotherapy induced febrile neutropenia patients aged 16-years and above of either gender using consecutive sampling methodology. They were enrolled at their index visit via emergency or oncology clinic requiring ward admission. These patients were followed from the day of hospital admission till discharge.
Patients with confirmed diagnosis of cancer and having history of receiving chemotherapy prior to episode of febrile neutropenia were included. They were excluded if the adult patient presented with febrile neutropenia as a result of their underlying disease, like, aplastic anaemia and myelodysplastic syndrome.
Also, patients with no history of chemotherapy were excluded.
Ethics Statement
Our study protocol was initially accepted from the Ethical Review Committee of our institution with ERC # 2948-Med-14. Therefore, written informed consent was taken from patients before asking them for study participation.
Ascertainment of Exposure
Trained interviewers screened and enrolled participants within 48 hours of hospital admission based on the standard definition of febrile neutropenia episode with a single oral temperature of 38.3˚C or, oral temperature of 38˚C which persists for more than an hour and an absolute neutrophil count of <1000 cells/mm 3 [1] . Patients were stratified into high {exposed} and low risk {non-exposed} based on MASCC score at the time of admission. The MASCC Score is calculated based on burden of illness, presence of hypotension, chronic obstructive pulmonary disease, fungal infection, solid tumor, outpatient status and age < 60 years [ Table 1 ].
Ascertainment of Outcome
Patient outcome was recorded by the trained interviewers as development of serious complications or not at the time of hospital discharge, based on presence or absence of any of the following: hypotension, respiratory failure, intensive care admission, disseminated intravascular coagulation, confusion or altered mental state, congestive cardiac failure, bleeding and renal failure. Length of hospital stay was recorded on discharge. Positive cultures were also recorded.
Covariables
Following covariables were recorded for each patient including demographic information, underlying cancer and chemotherapy, day one of chemotherapy, absolute neutrophil count (ANC), foci of infection, including any positive cultures. The application of G-CSF non-usage versus usage [along with the total number of days administered] was noted.
Operational Definitions Taken into Account
Patients were stratified as high risk if they had a MASCC score of less than 21
and low risk if score is equal to or more than 21 based on parameters mentioned in Table 1 
Sample Size Assumptions
The sample size was calculated by taking into consideration the study objectives.
Epi Info Version 6 was utilized to compute the sample size. The calculations were based on the assumption that reported proportion of serious complication for febrile neutropenia is 34% [9] . By taking into account this figure together with 95% CI, and exposed to non-exposed ratio of 1:1, with 80% power and risk ratio of 2.0, the sample size calculated to be n = 76. After adjusting for missing or incomplete information, the final sample size was approximately N = 84. 
Data Analysis Plan
Results
Data were collected for patients admitted with chemotherapy induced febrile neutropenia. A thorough review of the hospital medical records system revealed a total of 1471 patients who received chemotherapy between February till August 2014. However among these patients only 88 patients were admitted with chemotherapy induced febrile neutropenia and included for analysis ( Figure 1 ). Table 3 . The rate of serious complications is enlisted in Table 2 . Hypotension, respiratory failure and death were the most common complications. The factors associated with serious complications have been given in a cumulative form in Table 4 .
Tumour Types
MASCC Score in Accurately Predicting Risk of Seriou Complications
The sensitivity, specificity, positive and negative predictive value of MASCC 
Discussion
This study helped us find that MASCC risk-index score as a useful tool to identify patients at low risk of complications. Eighty five percent patients comprised the high risk group which is higher than the proportion of patients reported in Table 5 . MASCC score to predict presence or absence of serious medical complications. is thought to be due to less frequent use of quinolones and central lines [18] . In our study however prior history of prophylactic antibiotics and presence of central lines were not recorded.
Uys et al., in their study reported 75% mortality among the high risk bacteraemia patients. In the current study, however 11.7% in the high risk group with bacteraemia died.
There have been numerous randomized controlled trials to evaluate the efficacy of granulocyte colony stimulating factors (G-CSF) in FN patients, with results revealing effect on shortening the duration of neutropenia [21] [22] [23] .
However none of the studies reveal benefit in terms of reducing the duration of fever, cost or the use of antimicrobial therapy and no effect on reducing mortality. In patients with uncomplicated FN episode, G-CSF is hence not recommended [24] . In our study the use of G-CSF was not associated with decrease in serious complications, [p = 0.14].
There were several factors which were associated with a higher chance of developing serious complications. These factors included age > 60, MASCC score of <15 and an albumin <2.5 mg/dl. However no statistically significant association was found in risk of developing serious complications based on solid or haematological malignancy, ANC, haemoglobin, gender, length of hospital stay and bacteraemia. In a similar study by Baskaran et al., low albumin was associated with a higher chance of serious complications [9] . However in contrast to the present study there was no statistically significant difference found based on age. Based on our results we recommend that albumin be incorporated in the risk stratification.
In our patient population the sensitivity, specificity, positive and negative predictive value of MASCC score in accurately predicting risk of serious complications was 21.33%, 100%, 100% and 18.06% respectively. In another study from Asia, sensitivity, specificity, negative and positive and negative predictive value of MASCC score in predicting risk of serious complications was 81, 60, 52 and 86% respectively [25] . In another study reported from Malaysia, MASCC score predicted outcome with sensitivity, specificity, and positive predictive value of 93%, 67% and 83% respectively [9] . By far in our patient population MASCC score was more specific and with a greater positive predictive value in comparison to other studies however less sensitive. This study correctly predicted 100% of low risk and 21.3% of high risk patients hence indicating that our high risk patient population need further risk stratification. A total of seventy five patients were predicted to be in the high risk MASCC group and sixteen of them developed serious medical complications. This lead to an obvious finding of a low sensitivity which is in contrast to those reported in earlier studies. This may be attributable to a relatively smaller sample size of our study or it could be a finding by chance alone. The low sensitivity of our study implies a possibility that our high risk group possibly developed less serious complications when compared to international data, or this again could be a chance finding. A probable explanation of this could be that our patient population is different. Another justification is that this study is only representative of a single institution and the inference thus is always taken with caution.
To the best of our knowledge through literature search, we report that this is the first study which applies the MASCC score index in our patient population, from the developing country belt.
There are several strengths of this study; a cohort study design was selected which is ideal in forecasting the causal association of exposure with outcome.
Furthermore there was no loss in follow up or drop out of our cohort as these patients were followed up till hospital discharge. Our study has few limitations that need to be taken into account while interpreting the results. As we enrolled all the patients with febrile neutropenia during the study period hence it was hard to select and maintain an equal number of exposed and non-exposed patients. It shall be recognized that this is a single centre study conducted in a tertiary care centre. Hence, generalizability of our study results is reported with caution.
Unanswered Questions and Future Directions for Research
Data regarding the patients with FN who presented in the outpatient setting and
were not later admitted, would have helped in a robust data analysis, however such patients were not a part of this study.
Among the patients identified to be in the low risk group a prospective study could be done to treat them with oral antibiotics with possibility of an early dis-charge if a patient remains afebrile for more than 24 hours. This would help in reducing length of hospital stay and hence cost of medical treatment. Similar study has been done in the past by Klastersly et al., in which 44% low risk patients eligible for oral antibiotics were discharged home with a median time to discharge of 26 hours after they were afebrile for at least 24 hours [26] . Only 3.7% of these patients required readmission, however none of the 44% patients developed any serious medical complications [26] .
Conclusion
We conclude that MASCC risk index score is a tool which is helpful in identifying FN patients at low risk of complications. In future by applying this score it would help in treating high risk patients aggressively from the start and at the same time identifying low risk patients who may be treated less aggressively with a potential early discharge and marked reduction in hospital cost.
